

Press Release

Samsung Active Asset Management Launches KoAct US Brain Treatment Active ETF Benchmarked Against the Solactive US CNS Therapeutics Index

03 September 2024

FRANKFURT AM MAIN — Solactive is pleased to announce another collaboration with Samsung Active Asset Management. Samsung Active Asset Management has chosen the Solactive US CNS Therapeutics Index as the benchmark for its latest actively managed KoAct US Brain Treatment Active ETF. This collaboration highlights Solactive's capability of constructing indices in dynamic and high-growth sectors such as the central nervous system (CNS) therapeutics market.

The global CNS therapeutics market is estimated to be worth between \$147 billion and \$169 billion worldwide by 2027, increased from \$116 billion in 2022. Driven by factors such as the aging population, the increasing prevalence of neurodegenerative diseases, and increased awareness of CNS disorders, the market is poised for further growth, making it an attractive investment opportunity to capture such growth in the healthcare sector.¹

The [Solactive US CNS Therapeutics Index](#) is designed to track the performance of the top 20 US-listed companies actively involved in developing and commercializing therapies for CNS, psychiatric, and neurological disorders. These include a broad range of diseases, such as Alzheimer's, Parkinson's, depression, and epilepsy. The index provides investors with targeted exposure to this highly specialized sector, where innovation is critical to address the significant medical needs by developing complex treatments. The index selection utilizes an industry classification framework to screen companies, followed by using ARTIS®, Solactive's proprietary natural language processing technology. This advanced algorithm identifies companies making a significant contribution to actively developing CNS therapeutics, therefore offering a more relevant selection to constantly align with the current industry landscape. The top 3 companies are assigned with fixed weights of 20%, 15%, and 10%, respectively. The remaining companies are weighted by free-float market capitalization, with a maximum individual weight cap of 4%. This structure ensures diversified exposure, allowing investors to benefit from established companies' stability and emerging companies' growth potential.

The ETF listed on 3 September 2024 on the Korea Stock Exchange (KRX) with the ticker code 490330 KS.

¹ [Fostering Success in CNS Innovation](#)

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Michelle Zhang / Katerina Xagorari
PR & Communications
+49 (69) 719 160-311
press@solactive.com

Timo Pfeiffer, Chief Markets Officer at Solactive, commented: *"We are delighted to extend our partnership with Samsung Active Asset Management. The Solactive US CNS Therapeutics Index is an excellent example of how specialized indices can provide targeted exposure to dynamic sectors in the healthcare industry. Moreover, Solactive's ability to deliver efficient solutions with rapid implementation allows our clients to swiftly capitalize on market opportunities while maintaining a high standard of precision and customization."*

Beomjin Seo, Chief of Strategy Solution, Strategy Solution team at Samsung Active Asset Management commented: *"We are pleased to expand our partnership with Solactive with Korea's first active ETF to focus on "cures for brain diseases." KoAct is committed to offering diverse investment products with KoAct's insight and expertise in the form of active ETFs to investors to tap the potential growth in the market."*

For more information, please visit:

<http://www.solactive.com>

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Michelle Zhang / Katerina Xagorari
PR & Communications
+49 (69) 719 160-311
press@solactive.com

Note to editors

About Solactive

Solactive is a leading provider of indexing, benchmarking, and calculation solutions for the global investment and trading community. Headquartered in Frankfurt and, with offices in Hong Kong, Toronto, Berlin, Dresden, and Amsterdam, we innovate and disrupt the status quo as the partner of choice for our clients.

The unique blend of our 300 staff's expertise in data, data science, financial markets, and technology enables our clients' continued success through the delivery of a superior experience, unique customization capabilities, and the best value for money available in the industry. With more than 30,000 indices calculated daily, we offer a full suite of solutions, including market-leading ESG and thematic indices.

As at January 2024, Solactive served approximately 500 clients across the world, with approximately US\$300 billion invested in products linked to our indices. Solactive is registered with ESMA as a benchmark administrator and is supervised by the BaFin.

Disclaimer

The information in this document does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. Solactive AG and all other companies mentioned in this document are not responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.

Solactive AG, Platz der Einheit 1, 60327 Frankfurt am Main, Germany. Registered Office: Frankfurt am Main, Registration Court: Amtsgericht Frankfurt am Main, HRB: 79986, USt-IdNr.: DE 255 598 976. Management Board: Steffen Scheuble, and Timo Pfeiffer, Head of Supervisory Board: Dr Felix Mühlhäuser.

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Michelle Zhang / Katerina Xagorari
PR & Communications
+49 (69) 719 160-311
press@solactive.com